MYT NETHERLANDS PARENT BV (MYTE) Fundamental Analysis & Valuation

NYSE:MYTEUS55406W1036

Current stock price

7.64 USD
-0.2 (-2.55%)
Last:

This MYTE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MYTE Profitability Analysis

1.1 Basic Checks

  • In the past year MYTE was profitable.
  • MYTE had a negative operating cash flow in the past year.
  • MYTE had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MYTE reported negative operating cash flow in multiple years.
MYTE Yearly Net Income VS EBIT VS OCF VS FCFMYTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -5.01%, MYTE is doing worse than 68.85% of the companies in the same industry.
  • MYTE has a Return On Equity (-8.64%) which is in line with its industry peers.
  • MYTE has a worse Return On Invested Capital (0.05%) than 63.93% of its industry peers.
Industry RankSector Rank
ROA -5.01%
ROE -8.64%
ROIC 0.05%
ROA(3y)-2.35%
ROA(5y)-2.32%
ROE(3y)-3.64%
ROE(5y)-1.89%
ROIC(3y)N/A
ROIC(5y)N/A
MYTE Yearly ROA, ROE, ROICMYTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 5 -5

1.3 Margins

  • The Operating Margin of MYTE (0.03%) is worse than 63.93% of its industry peers.
  • MYTE has a Gross Margin of 47.04%. This is in the better half of the industry: MYTE outperforms 72.13% of its industry peers.
  • MYTE's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.03%
PM (TTM) N/A
GM 47.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y-0.15%
MYTE Yearly Profit, Operating, Gross MarginsMYTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

4

2. MYTE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MYTE is destroying value.
  • Compared to 1 year ago, MYTE has more shares outstanding
  • MYTE has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, MYTE has an improved debt to assets ratio.
MYTE Yearly Shares OutstandingMYTE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MYTE Yearly Total Debt VS Total AssetsMYTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 4.23 indicates that MYTE is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of MYTE (4.23) is better than 86.07% of its industry peers.
  • MYTE has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of MYTE (0.19) is better than 61.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 4.23
ROIC/WACC0.01
WACC7.41%
MYTE Yearly LT Debt VS Equity VS FCFMYTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.78 indicates that MYTE should not have too much problems paying its short term obligations.
  • MYTE has a Current ratio of 1.78. This is in the better half of the industry: MYTE outperforms 76.23% of its industry peers.
  • A Quick Ratio of 0.22 indicates that MYTE may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.22, MYTE is doing worse than 85.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 0.22
MYTE Yearly Current Assets VS Current LiabilitesMYTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

6

3. MYTE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 525.00% over the past year.
  • Looking at the last year, MYTE shows a quite strong growth in Revenue. The Revenue has grown by 11.84% in the last year.
  • The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)525%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)11.84%
Revenue growth 3Y11.16%
Revenue growth 5Y17.27%
Sales Q2Q%13.17%

3.2 Future

  • Based on estimates for the next years, MYTE will show a very strong growth in Earnings Per Share. The EPS will grow by 54.63% on average per year.
  • MYTE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.58% yearly.
EPS Next Y291%
EPS Next 2Y115.23%
EPS Next 3Y54.63%
EPS Next 5YN/A
Revenue Next Year9.06%
Revenue Next 2Y9.71%
Revenue Next 3Y9.58%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MYTE Yearly Revenue VS EstimatesMYTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
MYTE Yearly EPS VS EstimatesMYTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

3

4. MYTE Valuation Analysis

4.1 Price/Earnings Ratio

  • MYTE is valuated quite expensively with a Price/Earnings ratio of 27.29.
  • The rest of the industry has a similar Price/Earnings ratio as MYTE.
  • Compared to an average S&P500 Price/Earnings ratio of 25.35, MYTE is valued at the same level.
  • The Price/Forward Earnings ratio is 18.32, which indicates a rather expensive current valuation of MYTE.
  • Based on the Price/Forward Earnings ratio, MYTE is valued a bit cheaper than 61.48% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.61, MYTE is valued at the same level.
Industry RankSector Rank
PE 27.29
Fwd PE 18.32
MYTE Price Earnings VS Forward Price EarningsMYTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MYTE indicates a slightly more expensive valuation: MYTE is more expensive than 67.21% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 49.69
MYTE Per share dataMYTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MYTE's earnings are expected to grow with 54.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y115.23%
EPS Next 3Y54.63%

0

5. MYTE Dividend Analysis

5.1 Amount

  • No dividends for MYTE!.
Industry RankSector Rank
Dividend Yield N/A

MYTE Fundamentals: All Metrics, Ratios and Statistics

MYT NETHERLANDS PARENT BV

NYSE:MYTE (4/30/2025, 8:23:38 PM)

7.64

-0.2 (-2.55%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)02-11
Earnings (Next)05-14
Inst OwnersN/A
Inst Owner Change8.57%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.04B
Revenue(TTM)880.73M
Net Income(TTM)-35.85M
Analysts76.36
Price Target10.71 (40.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)151.51%
Min EPS beat(2)96.08%
Max EPS beat(2)206.95%
EPS beat(4)2
Avg EPS beat(4)50.27%
Min EPS beat(4)-50.98%
Max EPS beat(4)206.95%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.32%
Min Revenue beat(2)-3.03%
Max Revenue beat(2)0.39%
Revenue beat(4)1
Avg Revenue beat(4)-1.89%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)0.39%
Revenue beat(8)3
Avg Revenue beat(8)-0.99%
Revenue beat(12)4
Avg Revenue beat(12)-1.89%
Revenue beat(16)7
Avg Revenue beat(16)-0.73%
PT rev (1m)0%
PT rev (3m)49.57%
EPS NQ rev (1m)-140.01%
EPS NQ rev (3m)-111.77%
EPS NY rev (1m)0%
EPS NY rev (3m)17.95%
Revenue NQ rev (1m)-0.36%
Revenue NQ rev (3m)-1.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.97%
Valuation
Industry RankSector Rank
PE 27.29
Fwd PE 18.32
P/S 1.05
P/FCF N/A
P/OCF N/A
P/B 2.23
P/tB 3.57
EV/EBITDA 49.69
EPS(TTM)0.28
EY3.66%
EPS(NY)0.42
Fwd EY5.46%
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS7.27
BVpS3.42
TBVpS2.14
PEG (NY)0.09
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.01%
ROE -8.64%
ROCE 0.06%
ROIC 0.05%
ROICexc 0.05%
ROICexgc 0.07%
OM 0.03%
PM (TTM) N/A
GM 47.04%
FCFM N/A
ROA(3y)-2.35%
ROA(5y)-2.32%
ROE(3y)-3.64%
ROE(5y)-1.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y-0.15%
F-Score3
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA 4.11
Cap/Depr 47.13%
Cap/Sales 1.02%
Interest Coverage 0.05
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 0.22
Altman-Z 4.23
F-Score3
WACC7.41%
ROIC/WACC0.01
Cap/Depr(3y)134.72%
Cap/Depr(5y)94.09%
Cap/Sales(3y)2.03%
Cap/Sales(5y)1.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)525%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y291%
EPS Next 2Y115.23%
EPS Next 3Y54.63%
EPS Next 5YN/A
Revenue 1Y (TTM)11.84%
Revenue growth 3Y11.16%
Revenue growth 5Y17.27%
Sales Q2Q%13.17%
Revenue Next Year9.06%
Revenue Next 2Y9.71%
Revenue Next 3Y9.58%
Revenue Next 5YN/A
EBIT growth 1Y101.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year188.35%
EBIT Next 3Y67.88%
EBIT Next 5YN/A
FCF growth 1Y18.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-407.95%
OCF growth 3YN/A
OCF growth 5Y33.41%

MYT NETHERLANDS PARENT BV / MYTE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MYT NETHERLANDS PARENT BV (MYTE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MYTE.


What is the valuation status for MYTE stock?

ChartMill assigns a valuation rating of 3 / 10 to MYT NETHERLANDS PARENT BV (MYTE). This can be considered as Overvalued.


Can you provide the profitability details for MYT NETHERLANDS PARENT BV?

MYT NETHERLANDS PARENT BV (MYTE) has a profitability rating of 2 / 10.


What are the PE and PB ratios of MYT NETHERLANDS PARENT BV (MYTE) stock?

The Price/Earnings (PE) ratio for MYT NETHERLANDS PARENT BV (MYTE) is 27.29 and the Price/Book (PB) ratio is 2.23.


What is the financial health of MYT NETHERLANDS PARENT BV (MYTE) stock?

The financial health rating of MYT NETHERLANDS PARENT BV (MYTE) is 4 / 10.